Table 5.
Multivariate Tobit regression models on Direct Costs (Medication, Tests)
| Direct costs | Medication | Tests | ||||
|---|---|---|---|---|---|---|
| No PD | PD | No PD | PD | No PD | PD | |
| (Intercept) | 583.4 (478.0, 692.9) | 785.2 (643.2, 949.8) | 98.9 (50.3, 186.1) | 155.2 (100.7, 241.7) | 125.2 (60.6, 204.1) | 136.1 (90.1, 179.5) |
| Age | −3.1 (−14.8, 7.2) | −25.2 a (−40.9, −12.4) | −4.0 (−11.6, 1.5) | −5.1 (−12.9, 0.7) | 0.6 (−6.2, 6.9) | −5.5 (−11.1, −0.8) |
| Years with diagnosis | 2.4 (−6.9, 12.6) | 4.1 (−15.5, 21.6) | 3.2 (−1.6, 7.6) | 4.6 (−3.3, 17.0) | −1.3 (−6.9, 4.8) | −0.8 (−8.3, 4.2) |
| FIQ | 12.3 a (6.3, 20.2) | 20.8 a (7.1, 39.0) | 2.7 (−0.8, 9.0) | 1.6 (−3.2, 5.6) | 3.3 a (0.2, 6.6) | 5.2 a (0.9, 12.7) |
Note: Transformed Tobit coefficients with bootstrapped 95 % CIs (aindicating statistically significant coefficients –alpha = 0.05-). Explanatory variables centred to the sample mean. Accordingly, Intercept approximates the cost of a “mean individual” (aged 55.22, with 14.2 years with diagnosis, and a FIQ score of 56.36). For clarity, significant results are in bold